Literature DB >> 16554528

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Jonathan C Cohen1, Eric Boerwinkle, Thomas H Mosley, Helen H Hobbs.   

Abstract

BACKGROUND: A low plasma level of low-density lipoprotein (LDL) cholesterol is associated with reduced risk of coronary heart disease (CHD), but the effect of lifelong reductions in plasma LDL cholesterol is not known. We examined the effect of DNA-sequence variations that reduce plasma levels of LDL cholesterol on the incidence of coronary events in a large population.
METHODS: We compared the incidence of CHD (myocardial infarction, fatal CHD, or coronary revascularization) over a 15-year interval in the Atherosclerosis Risk in Communities study according to the presence or absence of sequence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) that are associated with reduced plasma levels of LDL cholesterol.
RESULTS: Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol and an 88 percent reduction in the risk of CHD (P=0.008 for the reduction; hazard ratio, 0.11; 95 percent confidence interval, 0.02 to 0.81; P=0.03). Of the 9524 white subjects examined, 3.2 percent had a sequence variation in PCSK9 that was associated with a 15 percent reduction in LDL cholesterol and a 47 percent reduction in the risk of CHD (hazard ratio, 0.50; 95 percent confidence interval, 0.32 to 0.79; P=0.003).
CONCLUSIONS: These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors. Copyright 2006 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554528     DOI: 10.1056/NEJMoa054013

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  926 in total

Review 1.  Progress in Defining the Genetic Basis of Diabetic Complications.

Authors:  Emma Dahlström; Niina Sandholm
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

2.  Identification of a novel LDLR mutation (c.261_262invGA, p.Trp87X): Importance of specifying DNA and protein mutations.

Authors:  David Ng; Emma Spaulding; James C Mullikin; Leslie G Biesecker
Journal:  Atherosclerosis       Date:  2010-04-20       Impact factor: 5.162

3.  PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.

Authors:  Mali Liu; Guoxin Wu; Jennifer Baysarowich; Michael Kavana; George H Addona; Kathleen K Bierilo; John S Mudgett; Guillaume Pavlovic; Ayesha Sitlani; John J Renger; Brian K Hubbard; Timothy S Fisher; Celina V Zerbinatti
Journal:  J Lipid Res       Date:  2010-05-07       Impact factor: 5.922

4.  The Role of Statin Therapy for Primary Prevention: What is the Evidence?

Authors:  Rebecca Rudominer Ascunce; Jeffrey S Berger; Howard S Weintraub; Arthur Schwartzbard
Journal:  Curr Atheroscler Rep       Date:  2012-01-29       Impact factor: 5.113

Review 5.  Drug development in the era of precision medicine.

Authors:  Sarah A Dugger; Adam Platt; David B Goldstein
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

6.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

Review 7.  Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.

Authors:  Evan A Stein; Frederick J Raal
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

Review 8.  Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.

Authors:  Davide Noto; Angelo B Cefalù; Maurizio R Averna
Journal:  Curr Atheroscler Rep       Date:  2014-06       Impact factor: 5.113

9.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

Review 10.  Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice.

Authors:  Kevin C Maki; Mary R Dicklin
Journal:  Curr Atheroscler Rep       Date:  2018-03-20       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.